1-3 of 3
Alexander Zimmerhackl
Close
Sort by
Journal Articles

Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma.

Klaus Podar, MD, PhD, Alexander Zimmerhackl, DI, Ursula Hainz, PhD, Mariateresa Fulciniti, PhD, Sonia Vallet, MD., Dian Olsen, MSc, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, Ph.D, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 1850.
https://doi.org/10.1182/blood.V114.22.1850.1850
Published: 2009
Journal Articles

The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma

Iris Breitkreutz, Marc S Raab, Olaf Christensen, Alexander Zimmerhackl, Jing Zhang, Simona Blotta, Teru Hideshima, Dharminder Chauhan, Scott Wilhelm, Kenneth C Anderson, MD, Klaus Podar, MD, MSc, PhD
Journal: Blood
Blood (2008) 112 (11): 2766.
https://doi.org/10.1182/blood.V112.11.2766.2766
Published: 2008
Journal Articles

Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity

Klaus Podar, MD, MSc, PhD, Jing Zhang, MS, Alexander Zimmerhackl, DI, Daniela Barila, PHD, Sonia Vallet, MD, Martin Sattler, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PHD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 2751.
https://doi.org/10.1182/blood.V112.11.2751.2751
Published: 2008